Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Darren DiSalvo

Daniel Kuzmich

Hossein Razavi

Can Mao

David S Thomson

John R Regan

Weimin Liu

Pier Francesco Cirillo

Charles Lawrence Cywin

Erick Richard Roush Young

Alan David Swinamer

Daniel Richard Marshall

Rajashekhar Betageri

John David Ginn

Brian Nicholas Cook

Pingrong Liu

John Lord

Christian Harcken

Eugene R Hickey

Ming-Hong Hao

Denice Mary Spero

Derek Cogan

Sanxing Sun

Tina Marie Morwick

Lifen Wu

Mario G Cardozo

Christopher Ronald Sarko

Jinhua Jeff Song

Ronald John Sorcek

Zhidong Chen

Michael Jason Burke

Peter Allen Nemoto

Qiang Zhang

Jiang-Ping Wu

Jonathan Timothy Reeves

Zhulin Tan

Jennifer A Kowalski

Daniel Robert Fandrick

Roman Wolfgang Fleck

Jonathan Emillian Emeigh

Brian Christopher Raudenbush

Erick Richard Young

Thomas Wai-ho Lee

Jochen Neu

Anthony S Prokopowicz, Iii

George Dahmann

Compounds of Formula (IA) wherein R, R, R, A, B, C, D, E, G, X, Y, and Z are as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof

Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.  Also disclosed are methods of making and methods of using same.

Pyrazolopiperidine compounds as CCR1 receptor antagonists

Disclosed indazoles compounds that are useful as antagonists of CCR1 activity and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Indazole compounds as CCR1 receptor antagonists

Azaindazole compounds as CCR1 receptor antagonists

Compounds of Formula (I) wherein R, R, R, R, R, R, and Rare as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof

Disclosed are novel compounds of formula (I): wherein R, Rand Rare as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Pyrimidine derivatives useful as inhibitors of PKC-theta

Disclosed are compounds of formula (I): wherein the variables R, R, Rand Z are described herein, which are useful as inhibitors of the kinase activity of the I&#x3ba;B kinase (IKK) complex. The compounds are therefore useful in the treatment of IKK mediated diseases including autoimmune diseases inflammatory diseases and cancer. Also disclosed are pharmaceutical compositions comprising these compounds and processes for preparing these compounds.

[object Object]

Disclosed are compounds of formula (I):wherein Rand Rare defined herein, which are useful as inhibitors of the kinase activity of the I&#x3ba;B kinase (IKK) complex. The compounds are therefore useful in the treatment of IKK mediated diseases including autoimmune diseases inflammatory diseases and cancer. Also disclosed are pharmaceutical compositions comprising these compounds and processes for preparing these compounds.

Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses

Growing community of inventors

New Milford, CT, United States of America

Darren DiSalvo